[en] Background. COVID-19 disease is an infectious disorder caused by SARS-CoV-2 virus, which has spread worldwide leading to a global pandemic, causing millions of deaths. After remission, a medley of symptoms is likely to remain, referred as post-acute COVID syndrome. Physical therapy, included in lung rehabilitation, could be a good approach to follow in these subjects who experiment COVID-19 sequels, accomplishing benefits especially in exercise tolerance, dyspnoea, and functional capability. In addition to de previous facts, the typical social isolation of this era suggests using technology in order to provide the required health care. Objective. To analyse the efficacy and viability of telerehabilitation versus in-person lung rehabilitation in post-acute COVID-19 syndrome patients. Methods. It is proposed a simple blind randomized controlled clinical trial, with patients recruited from "Complejo Hospitalario Universitario A Coruña" (CHUAC), "Hospital Marítimo de Oza" and "Centro de Salud de O Ventorrillo". Two groups will be compared, both of them will undergo the exact same 8-week lung rehabilitation program, one of them in presence-based modality and the other one remotely. Both groups will be involved in 3 weekly sessions of aerobic training, which will be implemented through a training station circuit and dosed by the modified Borg Scale (4-6) and theoretical maximum heart rate (30-60%). Furthermore, 2 weekly sessions will be devoted to strength training of peripheral muscles (2-3 series of repetitions until reaching 3-4 in the modified Borg Scale for the initial phase, and 5-6 for the final phase) and respiratory muscles, which will be conducted with the Threshold® IMT Breathing trainer (5 weekly sessions, from which 2 would be supervised, with 30% of PIM resistance and progressing a 6% every week until reaching 72%). Possible differences in exercise tolerance, dyspnoea, pulmonary function, quality of life, peripheral and respiratory muscle strength, functional capability and satisfaction will be analised.

[gl] Introducción. A enfermidade por COVID-19 é unha patoloxía infecciosa causada polo virus SARS-CoV-2, a cal se extendeu até o punto de xerar unha pandemia mundial, provocando milleiros de mortes. Tras a remisión da enfermidade, é posíbel que persista unha miscelánea de síntomas que pode ser nomeada como síndrome agudo post COVID-19. A Fisioterapia, incluida nos programas de rehabilitación pulmonar, podería ser un bo modelo a seguir neste tipo de suxeitos con secuelas post-COVID-19, actuando principalmente na tolerancia ao exercicio, a disnea e a capacidade funcional. Estos feitos, conxuntamente co illamento social característico desta pandemia, plantexan o uso das tecnoloxías como medio para brindar a atención sanitaria necesaria. Obxectivo. Analizar a efectividade e viabilidade da telerehabilitación en pacientes con síndrome agudo post-COVID-19 en contraposición con aqueles sometidos a rehabilitación pulmonar en modalidade presencial. Material e método. Plantéxase un ensaio clínico aleatorizado simple cego, para o cal se reclutarán pacientes do Complexo Hospitalario Universitario A Coruña (CHUAC), o Hospital Marítimo de Oza e o Centro de Saúde de O Ventorrillo. Compararáse a dous grupos, ambos sometidos a un programa de rehabilitación pulmonar de 8 semanas idéntico en forma, ca única salvedade da modalidade na que éste será impartido, un presencial e outro telemático. Realizarán 3 sesións semanais de entrenamento aeróbico, onde realizarán 30 minutos de exercicio cardiovascular mediante un circuito por estacións, cunha dosificación de 4-6 na escala de Borg modificada e ao 30-60% da frecuencia cardíaca máxima teórica. Ademais, realizarán 2 sesións semanais de fortalecemento muscular periférico (2-3 series de repeticións hasta chegar a 3-4 na escala de Borg modificada en fases iniciais e un 5-6 na parte final do programa) e fortalecemento da musculatura respiratoria mediante o Threshold® IMT Breathing trainer (5 sesións semanais, das cales 2 serán supervisadas, con resistencia ao 30% da PIM progresando semanalmente un 6% da PIM hasta chegar ao 72%). Analizaránse as posibles diferenzas entre grupos en canto a tolerancia ao exercicio, disnea, función pulmonar, calidade de vida, forza da musculatura periférica e respiratoria, funcionalidade e satisfacción ao finalizar a intervención e tras 3 meses.